Clinical Trial News and Research

RSS

AtheroNova starts AHRO-001 Phase 1 clinical trial for treatment of atherosclerosis

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the initiation of a Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers.

25 Jun 2013

Highland Therapeutics subsidiary reports positive HLD-200 Phase-1 results in ADHD patients

Highland Therapeutics, Inc., a specialty pharmaceutical company based in the MaRS Discovery District in Toronto, today announced that its wholly owned subsidiary has generated positive Phase-1 results for HLD-200 - a novel formulation of methylphenidate being developed to treat the symptoms associated with Attention-Deficit/Hyperactivity Disorder.

25 Jun 2013

Weight loss does not reduce heart disease risks among Type 2 diabetes patients: Study

A landmark study investigating the long-term effects of weight loss on the risks of cardiovascular disease among patients with Type 2 diabetes has now concluded, with significant results to be published today in the New England Journal of Medicine.

25 Jun 2013

CytRx reaches targeted enrollment in aldoxorubicin Phase 2b study for treatment of soft tissue sarcoma

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, announced that it has reached the targeted enrollment of 105 evaluable patients in its international Phase 2b clinical trial with aldoxorubicin as a first-line treatment for soft tissue sarcoma.

25 Jun 2013

Researchers test modified dendritic cells in patients with melanoma

In this issue of the Journal of Clinical Investigation, researchers led by Scott Pruitt at Duke University and Merck Research Laboratories report on a human clinical trial in which modified dendritic cells, a component of the immune system, were tested in patients with melanoma.

25 Jun 2013

Elcelyx's study shows NewMet has better glucose-lowering effects than metformin in type2 diabetic patients

Elcelyx Therapeutics announced today that clinical study results confirm that the primary site of action of Type 2 diabetes medicine metformin is in the lower bowel rather than in the circulation.

24 Jun 2013

Boehringer submits application to EMA for use of Pradaxa for treatment of acute DVT, PE

Boehringer Ingelheim today announced the submission of an application to the European Medicines Agency (EMA) for use of Pradaxa (dabigatran etexilate) for the treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE.

24 Jun 2013

HSG conducts clinical trial with novel drug formulation for treating Huntington disease

The Huntington Study Group (HSG), under the leadership of Samuel Frank, MD, Principal Investigator, (Boston University School of Medicine) and Claudia Testa, MD, PhD, co-Principal Investigator (Virginia Commonwealth University), is conducting a clinical trial with a formulation of the novel drug SD-809 in the treatment of HD the United States and Canada.

24 Jun 2013

Comprehend Systems collaborates with Merge eClinical to expands its clinical research space

Driven by increasing demand for its cloud-based data insights solution, Comprehend Systems further expands its reach in the clinical research space with a partnership with Merge Healthcare's eClinical Solutions division.

21 Jun 2013

New $11 million grant for lowering stroke risk among black and young populations

A new $11 million grant to Kaiser Permanente Northern California and UC San Francisco will support a multifaceted research program aimed at lowering stroke risk among black populations and younger stroke victims by targeting high blood pressure, also known as hypertension.

21 Jun 2013

New treatment option for patients with aortic stenosis

Robert Stoler, MD, FACC, FSCAI, director of the Cardiac Catheterization Lab at Baylor Heart and Vascular Hospital and co-medical director, Division of Cardiology, is leading Baylor's participation in an exciting clinical trial to research a new treatment option for AS patients.

From Medtronic 21 Jun 2013

Laughing gas is associated with increased risk for perioperative cardiac events

A clinical trial published in the July issue of Anesthesiology may shed some light on whether nitrous oxide ("laughing gas") causes an increased risk for cardiac events, including heart attacks after surgery, particularly among high-risk patients.

20 Jun 2013

Medicago produces Rotavirus VLP vaccine candidate using plant-based manufacturing platform

Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the successful production of a Rotavirus VLP vaccine candidate comprising all four structural antigens of rotavirus (VP2, VP4, VP6 and VP7) using Medicago's plant-based manufacturing platform.

20 Jun 2013

BerGenBio AS starts Phase 1 Clinical Trial for BGB324 oral AXL inhibitor

BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.

20 Jun 2013

Banyan Biomarkers completes $6 million series A funding for further biomarker research

Banyan Biomarkers, Inc. today announced that it has completed a $6 million series A funding from private investors for further biomarker research and continued development of a traumatic brain injury (TBI) diagnostic test. Currently, the company is enrolling subjects in a 2,000 patient pivotal clinical trial funded by a $26.3 million contract with the United States Department of Defense.

20 Jun 2013

Researchers launch clinical trial on stem cells to prevent amputations in end stage PAD

University Hospitals Case Medical Center clinical researchers have launched an innovative clinical trial, unique in its design, which will evaluate the ability of a patient's own stem cells to prevent leg amputations in end stage peripheral arterial disease (PAD).

20 Jun 2013

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced top line results of the Phase 4 SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin).

20 Jun 2013

Pharma IQ releases new infographic summary of results from industry survey

Pharma IQ is pleased to announce the release of a brand new infographic summary of the results from an industry survey conducted earlier this year.

From IQPC Ltd 19 Jun 2013

Ico Therapeutics completes Phase 2 iDEAL study for treatment of diabetic macular edema

iCo Therapeutics Inc. announced today that it has completed enrollment of its Phase 2 iDEAL study evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME). The study has shown a good safety profile with no drug-related serious adverse events to date.

19 Jun 2013

New framework to improve safety and effectiveness of surgical procedures, implantable devices

An international team of investigators co-led by Weill Cornell Medical College is offering a new framework for evidence-based surgery and device research, similar to the kind of risk and benefit analysis used in evidence-based medicine.

19 Jun 2013

Clinical Trial News and Research

AtheroNova starts AHRO-001 Phase 1 clinical trial for treatment of atherosclerosis

Highland Therapeutics subsidiary reports positive HLD-200 Phase-1 results in ADHD patients

Weight loss does not reduce heart disease risks among Type 2 diabetes patients: Study

CytRx reaches targeted enrollment in aldoxorubicin Phase 2b study for treatment of soft tissue sarcoma

Researchers test modified dendritic cells in patients with melanoma

Elcelyx's study shows NewMet has better glucose-lowering effects than metformin in type2 diabetic patients

Boehringer submits application to EMA for use of Pradaxa for treatment of acute DVT, PE

HSG conducts clinical trial with novel drug formulation for treating Huntington disease

Comprehend Systems collaborates with Merge eClinical to expands its clinical research space

New $11 million grant for lowering stroke risk among black and young populations

New treatment option for patients with aortic stenosis

Laughing gas is associated with increased risk for perioperative cardiac events

Medicago produces Rotavirus VLP vaccine candidate using plant-based manufacturing platform

BerGenBio AS starts Phase 1 Clinical Trial for BGB324 oral AXL inhibitor

Banyan Biomarkers completes $6 million series A funding for further biomarker research

Researchers launch clinical trial on stem cells to prevent amputations in end stage PAD

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Pharma IQ releases new infographic summary of results from industry survey

Ico Therapeutics completes Phase 2 iDEAL study for treatment of diabetic macular edema

New framework to improve safety and effectiveness of surgical procedures, implantable devices

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer